NASDAQ · AGEN
Healthcare · Biotechnology
$7.16
Up+$0.05 (+0.70%)
Updated Sep 16, 2026, 9:02 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AGEN closed at $7.16 after 20 trading sessions, down 4.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $7.05 | $7.19 | $6.81 | $7.16 | 779.52K |
| Sep 14, 2026 | $7.03 | $7.18 | $6.82 | $7.13 | 752.31K |
| Sep 11, 2026 | $6.93 | $7.02 | $6.70 | $6.94 | 790.46K |
| Sep 10, 2026 | $6.76 | $7.04 | $6.66 | $6.89 | 893.56K |
| Sep 9, 2026 | $7.595 | $7.605 | $6.782 | $6.86 | 1.45M |
| Sep 8, 2026 | $8.14 | $8.18 | $7.42 | $7.43 | 1.21M |
| Sep 4, 2026 | $8.14 | $8.38 | $7.99 | $8.24 | 986.85K |
| Sep 3, 2026 | $8.12 | $8.31 | $7.98 | $8.24 | 738.72K |
| Sep 2, 2026 | $8.07 | $8.28 | $7.685 | $8.09 | 664K |
| Sep 1, 2026 | $7.56 | $8.00 | $7.54 | $7.99 | 676.56K |
| Aug 31, 2026 | $7.68 | $7.76 | $7.50 | $7.61 | 721.03K |
| Aug 28, 2026 | $7.98 | $8.07 | $7.6137 | $7.66 | 741.16K |
| Aug 27, 2026 | $8.28 | $8.52 | $7.78 | $7.81 | 783.67K |
| Aug 26, 2026 | $8.30 | $8.40 | $8.03 | $8.25 | 779.94K |
| Aug 25, 2026 | $7.80 | $8.50 | $7.80 | $8.36 | 1.18M |
| Aug 24, 2026 | $8.07 | $8.07 | $7.60 | $7.67 | 775.16K |
| Aug 21, 2026 | $7.58 | $8.35 | $7.5768 | $8.09 | 1.52M |
| Aug 20, 2026 | $8.22 | $8.25 | $7.31 | $7.49 | 1.58M |
| Aug 19, 2026 | $7.66 | $8.7349 | $7.6199 | $8.26 | 2.29M |
| Aug 18, 2026 | $7.13 | $7.645 | $7.08 | $7.53 | 967.56K |
The latest Smart Investors Daily articles mentioning AGEN.
AGEN research
Company profile and research snapshot.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 30, 2026 | B. Riley Securities | Buy | — |
| Jul 13, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 10, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 28, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 31, 2026
LEXINGTON, Mass., August 31, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September.
Yahoo · Aug 28, 2026
LEXINGTON, Mass., August 28, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases.
ChartMill · Aug 27, 2026
AGEN passes Minervini Trend Template & High Growth Momentum screen. Strong price action, 98.2 RS, triple-digit EPS growth. Top momentum pick.
Benzinga · Aug 26, 2026
No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response, including 41% major
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGEN.
